Incyte/MSD’s immunotherapy combo fails in Phase III – PharmaTimes
PharmaTimes |
Incyte/MSD's immunotherapy combo fails in Phase III
PharmaTimes A late stage trial testing Incyte's epacadostat in combination with MSD's Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma. The companies had been hoping that the combination of the IDO1 inhibitor and … Incyte Falls After Phase 3 Flop, But The Sky Isn't Falling Incyte/Merck trial failure bodes ill for IDO class Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge |
